Palestinian Investing Ideas

Global Weekly Picks

CA$5.25
FV
9.3% undervalued intrinsic discount
770
users have viewed this narrative
3users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AU$0.4
FV
27.5% undervalued intrinsic discount
23.43%
Revenue growth p.a.
1.9k
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
9users have followed this narrative

Global Community

US$270
22.5% undervalued intrinsic discount
Fair Value
Revenue
27.02% p.a.
Profit Margin
52%
Future PE
28.5x
Price in 2031
US$444.48
CRMD logo
CorMedix

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Read more

View narrative
US$12
37.7% undervalued intrinsic discount
Fair Value
Revenue
38.8% p.a.
Profit Margin
51.99%
Future PE
3.42x
Price in 2031
US$16.82
US$433
19.2% undervalued intrinsic discount
Fair Value
Revenue
23.53% p.a.
Profit Margin
30.86%
Future PE
20.78x
Price in 2031
US$623.99
US$280
6.1% undervalued intrinsic discount
Fair Value
Revenue
11.71% p.a.
Profit Margin
10.14%
Future PE
36.93x
Price in 2031
US$411.54
US$173.02
84.8% undervalued intrinsic discount
Fair Value
Revenue
36.3% p.a.
Profit Margin
10%
Future PE
60x
Price in 2030
US$242.66
US$220
37.2% undervalued intrinsic discount
Fair Value
Revenue
9.64% p.a.
Profit Margin
14.22%
Future PE
10.42x
Price in 2036
US$512.69